Søgaard M, et al. - Considering the possible utility of rivaroxaban as an alternative to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism (VTE), researchers assess its safety and efficacy via examining the risk of recurrent VTE and major bleeding associated with rivaroxaban treatment of cancer-associated VTE. All adults with cancer-associated VTE initiating treatment with rivaroxaban were identified through linkage of nationwide Danish registries. They rarely recognized the use of rivaroxaban for cancer-associated VTE in this clinical practice setting. However, the treatment seemed safe and effective among those who received rivaroxaban with rates comparable to previous studies of selected populations.